Trial · NCT04804709
Adverse events31
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 31
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 11 |
| other | Platelet count decreased | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 3 | 3 | 10 |
| other | Hypokalemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 10 |
| other | Lymphocyte count decreased | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 20 |
| other | Hypophosphatemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 1 | 3 | 6 |
| other | Hyperglycemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 3 | 3 | 14 |
| other | hypermagnesemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 5 |
| other | Hypomagnesemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 1 | 3 | 1 |
| other | Hyperphosphatemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 1 | 3 | 1 |
| other | alanine aminotransferase increased | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 8 |
| other | Aspartate aminotransferase increased | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 2 | 3 | 10 |
| other | hypocalcemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 3 | 3 | 10 |
| other | Hypoalbuminemia | Blood and lymphatic system disorders | FUS Using Oral Panobinostat | 3 | 3 | 5 |
| other | Urinary tract infection | Infections and infestations | FUS Using Oral Panobinostat | 1 | 3 | 2 |
| other | Nausea | Gastrointestinal disorders | FUS Using Oral Panobinostat | 3 | 3 | 6 |
| other | Vomiting | Gastrointestinal disorders | FUS Using Oral Panobinostat | 2 | 3 | 4 |
| other | Flushing | Vascular disorders | FUS Using Oral Panobinostat | 2 | 3 | 2 |
| other | Otitis media | Infections and infestations | FUS Using Oral Panobinostat | 1 | 3 | 1 |
| other | Headache | Nervous system disorders | FUS Using Oral Panobinostat | 1 | 3 | 1 |
| other | Bradycardia | Cardiac disorders | FUS Using Oral Panobinostat | 1 | 3 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04804709/events